Pradaxa Being Reevaluated By FDA

Pradaxa (dabigatran), a relatively new anticoagulant used to treat non-valvular atrial fibrillation is being reassessed for safety by the FDA. Pradaxa is a fixed dose medication that is given twice daily and competes with Coumadin (warfarin), a more commonly used anticoagulant. Patients on Coumadin must have their blood monitored regularly, whereas Pradaxa does not require therapeutic monitoring.
Source: Pharmaceutical Online News - Category: Pharmaceuticals Source Type: news